The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer

SIMPLE SUMMARY: Several anti-angiogenic drugs have been approved for cancer treatment, alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug resistance, metastasis formation, and reduced delivery of chemotherapeutic agents, as a consequence of decrease of tumor v...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribatti, Domenico, Solimando, Antonio Giovanni, Pezzella, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304542/
https://www.ncbi.nlm.nih.gov/pubmed/34298648
http://dx.doi.org/10.3390/cancers13143433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304542/
https://www.ncbi.nlm.nih.gov/pubmed/34298648
http://dx.doi.org/10.3390/cancers13143433

Ejemplares similares